Brazil’s Hypera Pharma announced on Monday, March 2, that it has signed a contract to buy a portfolio of 18 pharmaceutical products from Japan’s Takeda for US$825 million, reported Reuters.
The portfolio includes the painkiller Neosaldina, as well as drugs Dramin and Nesina. Hypera Pharma claims that following the transaction it will become Brazil’s top pharma company.
Hypera has secured a 3.5 billion reais (US$779.49 million) credit line to pay for the acquisition, which is contingent on antitrust authorities and shareholder approval of the deal.
Full Content: Reuters
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
